| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/119704/2012 (17.2.12) |
| Publication Date | 17/02/2012 |
| Content Type | News |
|
The European Medicines Agency (EMA), in February 2012, recommended that the suspension of the marketing authorisations for aprotinin-containing medicines in the European Union be lifted. This follows a full review of the benefits and risks of all antifibrinolytic medicines, which found that the results of the BART study on which the suspension was based are unreliable. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/02/news_detail_001447.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp&jsenabled=true |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
